TWI848972B - 心臟肌小節抑制劑 - Google Patents

心臟肌小節抑制劑 Download PDF

Info

Publication number
TWI848972B
TWI848972B TW108131375A TW108131375A TWI848972B TW I848972 B TWI848972 B TW I848972B TW 108131375 A TW108131375 A TW 108131375A TW 108131375 A TW108131375 A TW 108131375A TW I848972 B TWI848972 B TW I848972B
Authority
TW
Taiwan
Prior art keywords
unsubstituted
substituted
group
alkyl
formula
Prior art date
Application number
TW108131375A
Other languages
English (en)
Chinese (zh)
Other versions
TW202023648A (zh
Inventor
布拉德利 摩根
馬克 范德瓦爾
路克 阿什克拉夫特
凱文 劉
智媛 莊
Original Assignee
美商胞質動力學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商胞質動力學公司 filed Critical 美商胞質動力學公司
Publication of TW202023648A publication Critical patent/TW202023648A/zh
Application granted granted Critical
Publication of TWI848972B publication Critical patent/TWI848972B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
TW108131375A 2018-08-31 2019-08-30 心臟肌小節抑制劑 TWI848972B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726162P 2018-08-31 2018-08-31
US62/726,162 2018-08-31

Publications (2)

Publication Number Publication Date
TW202023648A TW202023648A (zh) 2020-07-01
TWI848972B true TWI848972B (zh) 2024-07-21

Family

ID=67953902

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108131375A TWI848972B (zh) 2018-08-31 2019-08-30 心臟肌小節抑制劑

Country Status (21)

Country Link
US (4) US11414424B2 (enExample)
EP (1) EP3843842A1 (enExample)
JP (2) JP7447089B2 (enExample)
KR (1) KR20210068422A (enExample)
CN (2) CN118955409A (enExample)
AR (1) AR116283A1 (enExample)
AU (1) AU2019328556B2 (enExample)
BR (1) BR112021003496A2 (enExample)
CA (1) CA3110237A1 (enExample)
CL (1) CL2021000481A1 (enExample)
CO (1) CO2021003115A2 (enExample)
EA (1) EA202190657A1 (enExample)
EC (1) ECSP21016009A (enExample)
IL (2) IL281075B2 (enExample)
MA (1) MA53491A (enExample)
MX (1) MX2021002199A (enExample)
PH (1) PH12021550400A1 (enExample)
SG (1) SG11202101769YA (enExample)
TW (1) TWI848972B (enExample)
UY (1) UY38358A (enExample)
WO (1) WO2020047447A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE067913T2 (hu) 2018-01-19 2024-11-28 Cytokinetics Inc Dihidrobenzofurán és indén analógok mint szív szarkomer gátlók
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53489A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
WO2021183702A1 (en) * 2020-03-11 2021-09-16 Eubulus Biotherapeutics Inc. Gpx4 inhibitors, pharmaceutical compositions thereof, and their use for treating gpx4-mediated diseases
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
JP7700218B2 (ja) * 2020-09-17 2025-06-30 浙江海正薬業股▲ふん▼有限公司 ピペラジン誘導体、その製造方法、およびその使用
JP2023550444A (ja) * 2020-11-20 2023-12-01 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 トリアジンジオン系誘導体、その調製方法及びその医薬的応用
CN117083275A (zh) * 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
US20250288586A1 (en) 2022-04-26 2025-09-18 MyoKardia, Inc. Methods of Administering Myosin Inhibitors
WO2024050539A1 (en) 2022-09-02 2024-03-07 Cytokinetics, Incorporated Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde
WO2025096779A2 (en) 2023-11-01 2025-05-08 Bristol Myers Squibb Company Methods of treatment with a myosin inhibitor using protein levels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205223A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Pyrimidinedione compounds against cardiac conditions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5919785A (en) * 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2002501271A (ja) 1998-01-26 2002-01-15 ウェスターマン，ウェイン 手操作入力を統合する方法および装置
WO2003059265A2 (en) * 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
JPWO2004094424A1 (ja) * 2003-04-21 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその用途
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
AU2005312048B2 (en) * 2004-11-30 2012-08-02 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
WO2014205234A1 (en) 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
CN111393414B (zh) 2015-01-22 2024-05-07 迈奥卡迪亚公司 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
CN108430997B (zh) 2015-12-17 2021-06-04 先正达参股股份有限公司 杀微生物的噁二唑衍生物
CN108368098B (zh) 2015-12-18 2022-01-28 先正达参股股份有限公司 杀微生物的噁二唑衍生物
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
WO2018089433A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
HUE067913T2 (hu) 2018-01-19 2024-11-28 Cytokinetics Inc Dihidrobenzofurán és indén analógok mint szív szarkomer gátlók
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53489A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
FI3999180T3 (fi) 2019-07-17 2024-06-18 Cytokinetics Inc (r)-n-(5-(5-etyyli-1,2,4-oksadiatsol-3-yyli)-2,3-dihydro-1h-inden-1–yyli)-1–metyyli-1h-pyratsoli-4-karboksamidin polymorfeja
EP3999038B1 (en) 2019-07-17 2024-01-10 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
AU2020378197A1 (en) 2019-11-10 2022-05-26 MyoKardia, Inc. Methods of treatment with myosin modulator
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
CN114456163B (zh) 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843B (zh) 2020-11-19 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JP2023550444A (ja) 2020-11-20 2023-12-01 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 トリアジンジオン系誘導体、その調製方法及びその医薬的応用
CN114539257B (zh) 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
WO2022111498A1 (zh) 2020-11-24 2022-06-02 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
WO2024050539A1 (en) 2022-09-02 2024-03-07 Cytokinetics, Incorporated Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205223A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Pyrimidinedione compounds against cardiac conditions

Also Published As

Publication number Publication date
KR20210068422A (ko) 2021-06-09
TW202023648A (zh) 2020-07-01
US11414424B2 (en) 2022-08-16
EP3843842A1 (en) 2021-07-07
MA53491A (fr) 2021-09-15
US11952381B2 (en) 2024-04-09
US20240368172A1 (en) 2024-11-07
US20200109148A1 (en) 2020-04-09
IL281075B1 (en) 2024-10-01
AU2019328556B2 (en) 2025-09-04
JP2021535164A (ja) 2021-12-16
CL2021000481A1 (es) 2021-07-23
CO2021003115A2 (es) 2021-06-10
EA202190657A1 (ru) 2021-07-22
JP7447089B2 (ja) 2024-03-11
PH12021550400A1 (en) 2021-12-06
US20230090256A1 (en) 2023-03-23
CA3110237A1 (en) 2020-03-05
SG11202101769YA (en) 2021-03-30
US20250276976A1 (en) 2025-09-04
AU2019328556A1 (en) 2021-03-11
JP2024054409A (ja) 2024-04-16
WO2020047447A1 (en) 2020-03-05
CN118955409A (zh) 2024-11-15
AR116283A1 (es) 2021-04-21
CN112867539A (zh) 2021-05-28
ECSP21016009A (es) 2021-05-31
BR112021003496A2 (pt) 2021-05-18
US12275741B2 (en) 2025-04-15
IL281075B2 (en) 2025-02-01
MX2021002199A (es) 2021-08-16
UY38358A (es) 2020-03-31
IL281075A (en) 2021-04-29
CN112867539B (zh) 2024-08-06
IL315709A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
TWI848972B (zh) 心臟肌小節抑制劑
TWI835770B (zh) 心肌節抑制劑
US11014922B2 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors
CN114867727A (zh) Tau蛋白靶向化合物及相关使用方法
CN109983001A (zh) 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
WO2019089868A1 (en) Diazaspiro rock inhibitors
WO2018089353A1 (en) 3-substituted propionic acids as alpha v integrin inhibitors
TW201534606A (zh) 醛固酮合成酶抑制劑
CN105189508B (zh) 作为janus激酶抑制剂的环烷基腈吡唑并吡啶酮
CN116670123A (zh) 芳香杂环类化合物、药物组合物及其应用
EP4561552A2 (en) Cdk2 inhibitors and methods of using the same
WO2024097953A1 (en) Naphthyridine compounds for inhibition of raf kinases
TW202440091A (zh) Ｎａｍｐｔ調節劑
HK40054614A (en) Cardiac sarcomere inhibitors
HK40054614B (zh) 心脏肌小节抑制剂
EA045362B1 (ru) Ингибиторы саркомера сердца
BR112019009199B1 (pt) Compostos de ácidos propiônicos 3-substituídos, composição farmacêutica e seus usos como inibidores de alfa v integrina